Journal of Human Reproductive Sciences

ORIGINAL ARTICLE
Year
: 2014  |  Volume : 7  |  Issue : 2  |  Page : 93--98

Autologous stem cell transplantation in refractory Asherman«SQ»s syndrome: A novel cell based therapy


Neeta Singh, Sujata Mohanty, Tulika Seth, Meenakshi Shankar, Sruthi Bhaskaran, Sona Dharmendra 
 Department of Obstetrics and Gynaecology and Stem Cell Facility, All India Institute of Medical Sciences, New Delhi, India

Correspondence Address:
Neeta Singh
Department of Obstetrics and Gynecology, Room No. 3090A, Third Floor, All India Institute of Medical Sciences, Ansari Nagar, New Delhi - 110 029
India

Background : There is substantial evidence that adult stem cell populations exist in human endometrium, and hence it is suggested that either endogenous endometrial stem/progenitor cells can be activated or bone marrow derived stem cells can be transplanted in the uterine cavity for endometrial regeneration in Asherman«SQ»s syndrome (AS). Aims and Objectives : The objective was to evaluate the role of sub-endometrial autologous stem cell implantation in women with refractory AS in attaining menstruation and fertility. Setting : Tertiary care referral center. DESIGN: Prospective case series. Materials and Methods : Six cases of refractory AS with failed standard treatment option of hysteroscopic adhesiolysis in the past were included. Mononuclear stem cells (MNCs) were implanted in sub-endometrial zone followed by exogenous oral estrogen therapy. Endometrial thickness (ET) was assessed at 3, 6, and 9 months. RESULTS: Descriptive statistics and statistical analysis of study variables was carried out using STATA version 9.0. The mean MNC count was 103.3 × 106 (±20.45) with mean CD34+ count being 203,642 (±269,274). Mean of ET (mm) at 3 months (4.05 ± 1.40), 6 months (5.46 ± 1.36) and 9 months (5.48 ± 1.14) were significantly (P < 0.05) increased from pretreatment level (1.38 ± 0.39). Five out of six patients resumed menstruation. Conclusion : The autologous stem cell implantation leads to endometrial regeneration reflected by restoration of menstruation in five out of six cases. Autologous stem cell implantation is a promising novel cell based therapy for refractory AS.


How to cite this article:
Singh N, Mohanty S, Seth T, Shankar M, Bhaskaran S, Dharmendra S. Autologous stem cell transplantation in refractory Asherman's syndrome: A novel cell based therapy.J Hum Reprod Sci 2014;7:93-98


How to cite this URL:
Singh N, Mohanty S, Seth T, Shankar M, Bhaskaran S, Dharmendra S. Autologous stem cell transplantation in refractory Asherman's syndrome: A novel cell based therapy. J Hum Reprod Sci [serial online] 2014 [cited 2020 Jul 10 ];7:93-98
Available from: http://www.jhrsonline.org/article.asp?issn=0974-1208;year=2014;volume=7;issue=2;spage=93;epage=98;aulast=Singh;type=0